Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
921-940 of 1,743 trials

Plasmablastic Lymphoma: Daratumumab with Bortezomib and Dexamethasone

We are studying a combination of daratumumab, bortezomib, and dexamethasone for patients with relapsed or refractory plasmablastic lymphoma. The goal is to see if this treatment improves outcomes for those who cannot undergo stem cell transplantation.

Relapsed or Refractory Plasmablastic Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Myelodysplastic Syndrome: Targeted Treatment After Stem Cell Transplant

We are studying a new approach to prevent relapse and improve survival in patients with myelodysplastic syndrome after stem cell transplantation. The trial focuses on those with minimal residual disease to see if personalized treatment can help.

Myelodysplastic Syndrome>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Solid Tumors: 68Ga-FAPI-46 PET-CT Imaging Study

We are testing a new imaging method to see if it can better identify issues in solid tumors when previous scans were unclear. This study aims to improve risk assessment and safety for patients with various tumor types.

Solid Tumor>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Prostate Cancer: Radium-223 and Docetaxel Study

We are exploring whether using Radium-223 followed by Docetaxel helps men with bone-only metastatic prostate cancer feel better and live longer. This study will compare the effects of these treatments on quality of life and survival.

Metastatic Castration-Resistant Prostate CancerSymptomatic Bone-Only Metastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

NVDX3 Implant: Long-Term Safety Study

We are examining the long-term safety of the NVDX3 osteogenic implant made from human tissue. This study aims to ensure it is safe for patients who may need this type of treatment.

Low Grade Degenerative Lumbar SpondylolisthesisDistal Radius Fracture>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOrthopedics and Traumatology

Cirrhosis: Carvedilol for Prevention

We are studying whether low-dose carvedilol can help prevent complications or death in patients with asymptomatic cirrhosis. This trial focuses on individuals with specific liver conditions to see if the medication is effective and safe.

Alcoholic Cirrhosis>2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementHepatologyInternal Medicine

Myeloma Treatment: SAR446523 Injection

We are investigating a new injection for adults with relapsed or refractory myeloma. The study aims to determine its safety and effectiveness compared to current treatments.

Refractory Plasma Cell Myeloma>2 yearsSafety phase (I)HematologyOncology

Long-term Safety of Genetically Modified T Cell Therapy

We are following up with patients who received genetically modified T cells to assess their long-term safety and survival. This study aims to understand how well the treatment works and any potential risks involved.

Acute Lymphoblastic LeukemiaSystemic Lupus ErythematosusNon-Hodgkin's Lymphoma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncologyRheumatology

Multiple Sclerosis in Kids: Ofatumumab and Siponimod Study

We are comparing two new treatments, ofatumumab and siponimod, to fingolimod in children with multiple sclerosis. The study aims to see if these new options are as effective and safe for managing their condition.

Multiple Sclerosis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurologyPediatrics

Enterococcus faecalis Endocarditis: Continuous Infusion Antibiotics Study

We are studying whether continuous infusion of ampicillin and ceftriaxone is as effective as standard treatment for patients with Enterococcus faecalis infective endocarditis. This may help improve treatment outcomes and reduce complications.

Enterococcal Endocarditis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInfectious Diseases

Adnexal Torsion: Contrast-Enhanced Ultrasound Study

We are testing a new ultrasound method to see if it helps diagnose adnexal torsion more accurately than standard methods. This could reduce unnecessary surgeries and improve care for patients with suspected torsion.

Adnexal Torsion>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsInternal Medicine

Felzartamab for Late Antibody-Mediated Rejection

We are studying whether Felzartamab can help patients experiencing late antibody-mediated rejection after a transplant. This research aims to improve treatment options for these patients.

Late Antibody Mediated Renal Transplant Rejection>2 yearsEfficacy phase (II)Internal MedicineNephrology

Ovarian Cancer: Olaparib and Durvalumab Study

We are exploring whether Olaparib alone or with Durvalumab can be safely given to patients with high-grade ovarian cancer before surgery. This study may help us learn more about treatment effectiveness and safety.

Ovarian Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Liver Fibrosis Assessment: 68Ga-FAPI Imaging Study

We are studying a new imaging technique to evaluate liver fibrosis in patients with suspected nonalcoholic steatohepatitis. This may help improve the accuracy of liver damage assessments compared to standard methods.

Non-Alcoholic Steatohepatitis (NASH)>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyHepatologyInternal Medicine

Heart Attack Treatment: Timing of Medications

We are studying how the timing of beta blockers, ACE inhibitors, and SGLT2 inhibitors affects heart function in people who have had a heart attack. This may help us understand the best way to use these medications for better recovery.

Heart Attack>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Multiple Myeloma: Belantamab Mafodotin and Venetoclax Combination

We are testing a new combination treatment for patients with relapsed and refractory t(11;14) multiple myeloma. The goal is to see if this approach improves outcomes compared to current therapies.

Relapsed/Refractory Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)HematologyOncology

Cardiogenic Shock: Beta Receptor Modulation Trial

We are testing a new approach to manage heart function in patients with cardiogenic shock on V-A ECMO. This study compares reducing beta receptor stimulation to the usual treatment to see which is safer and more effective.

Cardiogenic Shock>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Tarlatamab for Extensive Stage Small Cell Lung Cancer

We are testing a new subcutaneous treatment for individuals with extensive stage small cell lung cancer. The goal is to see how well it works compared to current options.

Extensive Stage Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Unresectable Malignant Mesothelioma: Tremelimumab Study

We are comparing a new treatment called tremelimumab to a placebo for patients with unresectable malignant mesothelioma. The goal is to see if it improves survival and overall health outcomes.

Malignant Mesothelioma>2 yearsEfficacy phase (II)Investigational MedicinesOncology

Cognitive Disorders: BioFINDER 2 Study

We are investigating new imaging methods to better diagnose Alzheimer's disease in healthy older adults and those with early cognitive symptoms. The goal is to understand brain changes that may lead to dementia.

Dementia and Neurodegenerative Disorders>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNeurology